AGAnjali K. Gupta

Anjali K. Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anjali K. Gupta has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Rosemarie Mick

    Biostatistics and Epidemiology, University of Pennsylvania

    4 shared publications
  • George J. Cerniglia

    Department of Radiation Oncology|University of Pennsylvania

    3 shared publications
  • Ruth J. Muschel

    Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    3 shared publications
  • George J Cerniglia

    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

    2 shared publications
  • Stephen M. Hahn

    Department of Radiation Oncology|University of Pennsylvania

    2 shared publications
  • Vincent J Bakanauskas

    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

    2 shared publications

Latest Publications

  • Open Access

    The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response

    by Anjali K. Gupta, Bin Li, George J. Cerniglia, Mona S. Ahmed, Stephen M. Hahn, Amit Maity


  • HIV Protease Inhibitors Block Akt Signaling and Radiosensitize Tumor Cells Both In vitro and In vivo

    by Anjali K. Gupta, George J. Cerniglia, Rosemarie Mick, W. Gillies McKenna, Ruth J. Muschel

    In tumor cells with mutations in epidermal growth factor receptor (SQ20B), H-Ras (T24), or K-Ras (MIAPACA2 and A549), the inhibition of Akt phosphorylation increases radiation sensitivity in clonogenic assays, suggesting that Akt is a potential molecular target when combined with therapeutic radiation. Insulin resistance and diabetes are recognized side effects of HIV protease inhibitors (HPIs), suggesting that these agents may inhibit Akt signaling. Because activation of the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is common in human cancers, we hypothesized that HPIs can inhibit Akt activity resulting in increased tumor cell sensitivity to ionizing radiation–induced cell death. Five first-generation HPIs were subsequently tested and three of the five (amprenavir, nelfinavir, and saquinavir but not ritonavir or indinavir) inhibited Akt phosphorylation at Ser473 at serum concentrations routinely achieved in HIV patients. In both tumor cell colony formation assays and tumor regrowth delay experiments, combinations of drug and radiation exerted synergistic effects compared with either modality alone. In addition, in vivo, doses of amprenavir or nelfinavir comparable with the therapeutic levels achieved in HIV patients were sufficient to down-regulate phosphorylation of Akt in SQ20B and T24 xenografts. Finally, overexpression of active PI3K in cells without activation of Akt resulted in radiation resistance that could be inhibited with HPIs. Because there is abundant safety data on HPIs accumulated in thousands of HIV patients over the last 5 years, these agents are excellent candidates to be tested as radiation sensitizers in clinical trials.


  • Signaling Pathways in NSCLC as a Predictor of Outcome and Response to Therapy

    by Anjali K. Gupta, Daniel E. Soto, Michael D. Feldman, Jeffrey D. Goldsmith, Rosemarie Mick, Stephen M. Hahn, Mitchell Machtay, Ruth J. Muschel, W. Gillies McKenna

    The 5-year survival rate for patients with stage III non-small cell lung cancer (NSCLC) is 10%. A number of genetic alterations are associated with this disease including mutations and amplifications of EGFR (70%) and Ras (20–30%), both of which are upstream of PI3K. Our previous data show that these regulate tumor radiation sensitivity. Here we ask whether the activation of this pathway has prognostic relevance in NSCLC. Two series of patients were retrospectively analyzed. The first series consisted of 23 Stage III NSCLC patients treated preoperatively with a chemo/radiation protocol. The second consisted of 12 Stage III NSCLC patients treated with chemo/radiation without surgery who had survived more than 2 years. Expression levels of EGFR and Her-2 were assessed by immunohistochemical staining. PI3K signaling was evaluated by staining for phosphorylated Akt (P-Akt), a downstream target of PI3K. The staining for EGFR, Her-2, and P-Akt were related to outcome in the two groups. Additionally, the importance of PI3K signaling was evaluated in 3 NSCLC cell lines using a pharmacological blockade of PI3K by LY294002. In the first series of patients, 43% were positive for EGFR, 5% for Her-2, and 82.6% for P-Akt. Of the survivors, 25% were positive for EGFR, 0% for Her-2, and 42% for P-Akt. For P-Akt, this difference had a probability calculation of 0.003. The three NSCLC cell lines that we tested were found to have high levels of P-Akt. Pharmacologically inhibiting PI3K led to decreased Akt phosphorylation and radio sensitization of all three cell lines. The finding that NSCLC survivors treated by radiation have lower levels of PI3K and Akt signaling is consistent with the idea that inhibition of Akt leads to radio sensitization. This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation.


    • 15 September 2003
      • Vol. 63  (18) , 5656-68

    Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.

    by Thomas B Brunner, Stephen M Hahn, Anjali K Gupta, Ruth J Muschel, W Gillies McKenna, Eric J Bernhard

    This article presents an overview of preclinical studies and clinical trials of a number of independently derived farnesyltransferase inhibitors (FTIs). Potential targets and biological modes of action of FTIs are discussed, and the results of clinical trials are summarized. The significant efficacy of FTIs as single or combined agents in preclinical studies stands in contrast with only moderate effects in clinical Phase II-III trials. These results reveal a substantial gap in the understanding of the complex activity of FTIs and their interactions with cytotoxic agents. We conclude that the rational combination of FTIs with other therapies, taking into account the biological activities of the individual agents, may improve the clinical results obtained with FTIs.


  • Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002

    by Anjali K Gupta, George J Cerniglia, Rosemarie Mick, Mona S Ahmed, Vincent J Bakanauskas, Ruth J Muschel, W.Gillies McKenna


  • C-Raf-1 Protein Kinase Is Not Essential for Ras Transformation of Mouse Embryo Fibroblasts

    by Anjali K. Gupta, Eric Bernhard, Vincent J. Bakanauskas, George J. Cerniglia, Ruth J. Muschel, Gillies McKenna

    Transfection of primary cells with mutated oncogenic ras plus a cooperating oncogene such as myc results in the acquisition of the transformed cell phenotype. The pathways downstream of Ras that are required for transformation are an active topic of research. The Raf-MEKK-MAP kinase pathway is triggered by activation of Ras and thought to be important in Ras transformation of rodent fibroblasts. To further explore the involvement of this pathway, fibroblasts from homozygous knock out c-Raf-1 mouse embryos (20 KO) and wild-type c-Raf-1 mouse embryos (16 WT) were transfected with H-ras and mycV. The resulting cell line derived from the knock out cells grew slower both in tissue culture and had a longer latency period as tumors than the transformed cell line from the wild-type cells. Both cell lines were however able to form tumors in nude mice. These results suggest that c-Raf-1 is not required for Ras transformation in this system. Key Words: c-Raf-1, Ras, Transformation


    • 1 March 2002
      • Vol. 8  (3) , 885-92

    Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

    by Anjali K Gupta, W Gillies McKenna, Charles N Weber, Michael D Feldman, Jeffrey D Goldsmith, Rosemarie Mick, Mitchell Machtay, David I Rosenthal, Vincent J Bakanauskas, George J Cerniglia, et al.

    Locoregional recurrence is the dominant form of treatment failure in head and neck (H&N) cancer. The epidermal growth factor receptor (EGFR) is frequently amplified in this disease (<or=80%) and can lead to activation of phosphatidylinositol-3-kinase (PI3K), both directly and indirectly through Ras. We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome. In a series of 38 H&N cancer patients, overexpression of EGFR by immunohistochemical staining was assessed. PI3K signaling was evaluated by staining for phosphorylated Akt (P-Akt), a downstream target of PI3K. Both EGFR and P-Akt were then related to outcome. Radiation survival was determined in the SQ20B cell line, a radioresistant squamous cell line derived from a recurrent laryngeal cancer, after pharmacological blockade of EGFR with Iressa, of Ras by the FTI L744,832, or of PI3K by LY294002. A significant association was found between P-Akt staining and local control in the patient series. Two-year local control was 100% for patients staining 0-1+ for P-Akt as compared with 70.6% for patients staining 2-3+ (P = 0.04). In our series of 38 H&N cancers, 30 (78.9%) of the specimens were strongly (3+) positive for EGFR, whereas 25 (65.8%) were moderately to strongly (2-3+) positive for P-Akt. Pharmacologically inhibiting EGFR, Ras, and PI3K led to radiosensitization of SQ20B cells. Evaluation of PI3K activation by Akt phosphorylation might be a prognostic marker for response to therapy, and PI3K could be a useful target for therapy. These results also suggest that signaling from EGFR to PI3K can lead to radioresistance.